Geoffrey Porges
Stock Analyst at SVB Leerink
(1.41)
# 3,165
Out of 4,820 analysts
132
Total ratings
42.35%
Success rate
-6.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $22.78 | +145.83% | 10 | Dec 15, 2021 | |
| RDUS Radius Recycling | Maintains: Market Perform | $30 → $20 | $29.15 | -31.39% | 10 | Dec 9, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $8.41 | +1,089.06% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $599.21 | +41.85% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $59.25 | -18.99% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $279.84 | -22.81% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $180.37 | -25.15% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $11.00 | - | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $106.15 | -29.35% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $53.54 | - | 2 | Sep 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $29 → $10 | $9.54 | +4.82% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $0.32 | +9,277.93% | 8 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $493.71 | -64.55% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $10.53 | +697.72% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $37.50 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.41 | +867.74% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $6.79 | +798.38% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $119.51 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $22.78
Upside: +145.83%
Radius Recycling
Dec 9, 2021
Maintains: Market Perform
Price Target: $30 → $20
Current: $29.15
Upside: -31.39%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $8.41
Upside: +1,089.06%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $599.21
Upside: +41.85%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $59.25
Upside: -18.99%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $279.84
Upside: -22.81%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $180.37
Upside: -25.15%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $11.00
Upside: -
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $106.15
Upside: -29.35%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $53.54
Upside: -
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $9.54
Upside: +4.82%
Aug 10, 2021
Maintains: Outperform
Price Target: $35 → $30
Current: $0.32
Upside: +9,277.93%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $493.71
Upside: -64.55%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $10.53
Upside: +697.72%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $37.50
Upside: -
Nov 11, 2020
Initiates: Outperform
Price Target: $33
Current: $3.41
Upside: +867.74%
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $6.79
Upside: +798.38%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $119.51
Upside: -